New hope for kids with kidney disease: can dupilumab stop relapses?

NCT ID NCT07091175

Recruiting now Disease control Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if dupilumab, a drug already used for allergies, can help children with severe nephrotic syndrome stay relapse-free longer. About 66 kids aged 6–18 will get either dupilumab or a placebo injection for 6 months, while slowly reducing their steroid dose. The goal is to see if dupilumab can control the disease and reduce the need for steroids.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME IN CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic steroid-sensitive nephrotic syndrome nephrotic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEPHROTIC SYNDROME IN CHILDREN NEPHROTIC SYNDROME STEROID-DEPENDENT

Contacts and locations

Locations

KK Women's and Children's Hospital
RECRUITING

Singapore, Singapore, 229899, Singapore
National University Hospital
RECRUITING

Singapore, Singapore, 119228, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.